Cytotoxic agents have long been used in Behcet's syndrome, especially for eye involvement, but their effectiveness has been uncertain. We conducted a two-year randomized, placebo-controlled, double-blind trial of azathioprine (2.5 mg per kilogram of body weight per day) in Turkish men with Behcet's syndrome without eye disease (group 1; n = 25) or with eye disease (group 2; n = 48). Corticosteroid treatment remained available to all the patients. All six patients withdrawn from the study because of severe eye disease were receiving placebo (P less than 0.001). Azathioprine was superior to placebo in the prevention of new eye disease in group 1 (1 vs. 8 patients; P less than 0.01) and in group 2 among the 14 patients who at entry had disease in only one eye (P less than 0.001). There were fewer episodes of hypopyon uveitis (1 vs. 15; P less than 0.001) among the group 2 patients who took azathioprine. The patients taking azathioprine also had less frequent oral ulcers, genital ulcers, and arthritis. There were no serious side effects attributable to azathioprine. We conclude that azathioprine is effective in controlling the progression of Behcet's syndrome, especially its most serious manifestation, eye disease.
Source Information
Department of Rheumatology, Cerrahpasa Medical Faculty, University of Istanbul, Turkey.
This article has been cited by other articles:
Hatemi, G, Silman, A, Bang, D, Bodaghi, B, Chamberlain, A M, Gul, A, Houman, M H, Kotter, I, Olivieri, I, Salvarani, C, Sfikakis, P P, Siva, A, Stanford, M R, Stubiger, N, Yurdakul, S, Yazici, H
(2009). Management of Behcet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behcet disease. Ann Rheum Dis
68: 1528-1534
[Abstract][Full Text]
Hatemi, G, Silman, A, Bang, D, Bodaghi, B, Chamberlain, A M, Gul, A, Houman, M H, Kotter, I, Olivieri, I, Salvarani, C, Sfikakis, P P, Siva, A, Stanford, M R, Stubiger, N, Yurdakul, S, Yazici, H
(2008). EULAR recommendations for the management of Behcet disease. Ann Rheum Dis
67: 1656-1662
[Abstract][Full Text]
Niccoli, L., Nannini, C., Benucci, M., Chindamo, D., Cassara, E., Salvarani, C., Cimino, L., Gini, G., Lenzetti, I., Cantini, F.
(2007). Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study. Rheumatology (Oxford)
46: 1161-1164
[Abstract][Full Text]
Sfikakis, P. P., Markomichelakis, N., Alpsoy, E., Assaad-Khalil, S., Bodaghi, B., Gul, A., Ohno, S., Pipitone, N., Schirmer, M., Stanford, M., Wechsler, B., Zouboulis, C., Kaklamanis, P., Yazici, H.
(2007). Anti-TNF therapy in the management of Behcet's disease--review and basis for recommendations. Rheumatology (Oxford)
46: 736-741
[Full Text]
Gutfleisch, M., Spital, G., Mingels, A., Pauleikhoff, D., Lommatzsch, A., Heiligenhaus, A.
(2007). Pars plana vitrectomy with intravitreal triamcinolone: effect on uveitic cystoid macular oedema and treatment limitations. Br J Ophthalmol
91: 345-348
[Abstract][Full Text]
Baker, K B, Spurrier, N J, Watkins, A S, Smith, J R, Rosenbaum, J T
(2006). Retention time for corticosteroid-sparing systemic immunosuppressive agents in patients with inflammatory eye disease. Br J Ophthalmol
90: 1481-1485
[Abstract][Full Text]
Mat, C., Yurdakul, S., Uysal, S., Gogus, F., Ozyazgan, Y., Uysal, O., Fresko, I., Yazici, H.
(2006). A double-blind trial of depot corticosteroids in Behcet's syndrome. Rheumatology (Oxford)
45: 348-352
[Abstract][Full Text]
Tarzi, M. D., Lightman, S., Longhurst, H. J.
(2005). An exacerbation of Behcet's syndrome presenting with bilateral papillitis. Rheumatology (Oxford)
44: 953-954
[Full Text]
Kotter, I, Zierhut, M, Eckstein, A K, Vonthein, R, Ness, T, Gunaydin, I, Grimbacher, B, Blaschke, S, Meyer-Riemann, W, Peter, H H, Stubiger, N
(2003). Human recombinant interferon alfa-2a for the treatment of Behcet's disease with sight threatening posterior or panuveitis. Br J Ophthalmol
87: 423-431
[Abstract][Full Text]
Sfikakis, P P
(2002). Behcet's disease: a new target for anti-tumour necrosis factor treatment. Ann Rheum Dis
61: ii51-53
[Abstract][Full Text]
Alpsoy, E., Durusoy, C., Yilmaz, E., Ozgurel, Y., Ermis, O., Yazar, S., Basaran, E.
(2002). Interferon Alfa-2a in the Treatment of Behcet Disease: A Randomized Placebo-Controlled and Double-blind Study. Arch Dermatol
138: 467-471
[Abstract][Full Text]
Travis, S P L, Czajkowski, M, McGovern, D P B, Watson, R G P, Bell, A L
(2001). Treatment of intestinal Behcet's syndrome with chimeric tumour necrosis factor {alpha} antibody. Gut
49: 725-728
[Abstract][Full Text]
Sarigul, A., Koramaz, I., Demirturk, O., Boke, E., Sukru Mercan, A.
(2000). Pseudoaneurysm Formation in Surgically Treated Behcet's Syndrome: A Case Report. ANGIOLOGY
51: 349-354
[Abstract]
Barnes, C. G., Yazici, H.
(1999). Behcet's syndrome. Rheumatology (Oxford)
38: 1171-1174
[Full Text]
Demiroglu, H., Yalçin, S., Büyükasik, Y., Özcebe, O. I., Dündar, S.
(1998). Increased erythrocyte aggregation as an indicator for an aggressive clinical course in Behcet's disease: a prospective study. Ann Rheum Dis
57: 694-696
[Abstract][Full Text]
Kötter, I., Eckstein, A. K, Stübiger, N., Zierhut, M.
(1998). Treatment of ocular symptoms of Behcet's disease with interferon alpha 2a: a pilot study. Br J Ophthalmol
82: 488-494
[Abstract][Full Text]
Dick, A. D, Azim, M., Forrester, J. V
(1997). Immunosuppressive therapy for chronic uveitis: optimising therapy with steroids and cyclosporin A. Br J Ophthalmol
81: 1107-1112
[Full Text]
Lingenfelser, T., Duerk, H., Stevens, A., Grossmann, T., Knorr, M., Saal, J. G.
(1992). Generalized Myositis in Behcet Disease: Treatment with Cyclosporine. ANN INTERN MED
116: 651-653
[Abstract]
Heurkens, A. H. M., Westedt, M. L., Breedveld, F. C.
(1991). Prednisone Plus Azathioprine Treatment in Patients With Rheumatoid Arthritis Complicated by Vasculitis. Arch Intern Med
151: 2249-2254
[Abstract]
